Celladon to sell 4 million common shares through its public offering

Credit Suisse, Jefferies, Stifel, Wedbush PacGrow to assist with deal

By Devika Patel

Knoxville, Tenn., Aug. 7 – Celladon Corp. will sell 4 million common shares in its public sale with a 30-day greenshoe of 600,000 additional shares, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced July 30.

Credit Suisse and Jefferies are the joint bookrunning managers; Stifel and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for research and development; development of manufacturing capabilities; clinical development; general and administrative expenses; and general corporate purposes.

The clinical-stage biotechnology company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.